The epidemic of childhood obesity and the COVID-19 pandemic: metabolic characteristics and effects of therapy.

Publication date: Sep 07, 2026

The aim of the study was to analyse whether children whose obesity occurred during the pandemic differed metabolically from children who were obese earlier and to assess the effect of one-year treatment following the end of pandemic restrictions. A prospective study of 55 children aged 10-18 years who were referred to the outpatient’s clinic during the pandemic due to obesity was conducted. The following clinical data were analysed: time of obesity onset, body mass index (BMI) z-score, body mass composition, blood pressure, abdominal ultrasound, biochemical parameters of lipid and carbohydrate metabolism, aminotransferases and fetuin-A concentration. Participants received recommendations to improve their diet and increase physical activity (PA). After 3, 6 and 12 months, we assessed: BMI z-score, compliance with recommendations, and biochemical parameters. No significant differences between pandemic obesity and non-pandemic obesity were observed at the beginning and after one year. Children who followed the dietary recommendations had a significantly lower BMI z-score after 3 months (median 2. 08 vs. 1. 89, p = 0. 044). Children who reported increased PA (47. 3%) also showed lower BMI z-scores after 6 (median 2. 12 vs. 1. 86, p = 0. 53) and 12 months (median 2. 12 vs. 1. 78, p = 0. 008). The beneficial effect of PA was demonstrated in lower levels of fetuin-A in children with increased PA after 6 months (median 480 vs. 395 mg/ml, p = 0. 07). The “obesity pandemic” does not appear to be metabolically distinct from obesity that developed earlier and lasted longer. An increase in PA and compliance with dietary recommendations remain important elements of therapy, particularly in the context of metabolic complications. Fetuin-A may serve as a potential parameter for assessing compliance with PA recommendations and the rate of obesity progression.

Open Access PDF

Concepts Keywords
Adolescent
alpha-2-HS-Glycoprotein
alpha-2-HS-Glycoprotein
Body Mass Index
Child
COVID-19
COVID-19 pandemic obesity
Exercise
Female
fetuin-A.
Humans
Male
obesity
Pediatric Obesity
Prospective Studies
SARS-CoV-2

Semantics

Type Source Name
disease MESH childhood obesity
disease MESH COVID-19 pandemic
disease MESH obesity
drug DRUGBANK Coenzyme M
disease MESH Metabolic Bone Diseases
disease MESH overweight
disease MESH body weight
disease MESH weight gain
disease MESH insulin resistance
pathway KEGG Insulin resistance
disease MESH hypertension
disease MESH metabolic syndrome
disease MESH liver disease
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
drug DRUGBANK Cholesterol
disease MESH hos
drug DRUGBANK Dextrose unspecified form
disease MESH prediabetes
disease MESH impaired glucose tolerance
drug DRUGBANK Metformin
drug DRUGBANK Glutamic Acid
disease MESH anon
disease MESH dis
drug DRUGBANK Trestolone
drug DRUGBANK Nonoxynol-9
disease MESH weight loss
drug DRUGBANK Glycine
disease MESH tics
disease MESH NAFLD
disease MESH endocrine diseases
disease MESH car
disease MESH fatty liver
disease MESH dyslipidemia
disease MESH LMS
disease MESH BCM
disease MESH inflammation
drug DRUGBANK Tolbutamide
disease MESH diabetes mellitus

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *